A randomized Phase IIb study investigating oliceridine (TRV130) a novel µ-receptor G-protein pathway selective (μ-GPS) modulator for the management of moderate to severe acute pain following abdominoplasty

摘要

BackgroundOliceridine (TRV130), a novel μ-receptor G-protein pathway selective (μ-GPS) modulator, was designed to improve the therapeutic window of conventional opioids by activating G-protein signaling while causing low β-arrestin recruitment to the μ receptor. This randomized, double-blind, patient-controlled analgesia Phase IIb study was conducted to investigate the efficacy, safety, and tolerability of oliceridine compared with morphine and placebo in patients with moderate to severe pain following abdominoplasty (; oliceridine is an investigational agent not yet approved by the US Food and Drug Administration).